HES1 is a transcriptional repressor involved in cell differentiation and proliferation, but the expression pattern and biological roles of HES1 in breast cancer have not been examined. In this study, we examined HES1 expression in breast cancer tissues using immunohistochemistry and western blot analyses and investigated HES1 function using 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide and Matrigel invasion assays. Significant relationships were observed between HES1 upregulation and advanced tumour-node-metastasis stage (p = 0.011), node metastasis (p = 0.043), negative oestrogen receptor expression (p = 0.001) and triple-negative status (p = 0.001). HES1 overexpression was correlated with poor prognosis in breast cancer patients (p < 0.05), and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide and Matrigel invasion assays showed that silencing HES1 in MDA-MB-231 cells decreased cell proliferation and invasion, whereas overexpression of HES1 in MCF-7 cells enhanced cell proliferation and invasion. Further analyses showed that silencing HES1 downregulated p-AKT and impeded the epithelial-mesenchymal transition, whereas overexpression of HES1 upregulated AKT phosphorylation and induced epithelial-mesenchymal transition. Our study demonstrated that HES1 upregulation is a predictor of poor prognosis in human breast cancers and might be a critical contributor to the proliferation and invasion of breast cancer cells. Moreover, the proportion of HES1 overexpression in triple-negative breast cancer samples was significantly higher. Thus, HES1 might be a potential therapeutic target in the treatment of triple-negative breast cancer.
Introduction
Breast cancer is one of the most common malignancies, and it is the second leading cause of mortality in women. 1 Thus, new predictive biomarkers of tumour proliferation and targeted therapies are urgently needed. 2, 3 Hairy and enhancer of split homologue-1 (HES1) is a basic helixloop-helix (bHLH) transcriptional repressor. It is a mammalian counterpart of the Hairy and Enhancer of split protein and plays a critical role in many physiological processes and various morphogenetic events, including cellular differentiation, cell cycle arrest, apoptosis and self-renewal. [4] [5] [6] [7] HES1 can be induced by both the canonical and non-canonical Notch pathways. [8] [9] [10] [11] HES1 protein contains three conserved domains: the bHLH, Orange and WRPW domains. HES1 transcriptional repression is mediated through the bHLH domain, which binds to the N box (CACNAG) and Trp-Arg-Pro-Trp (WRPW) domains and interacts with the co-repressor transducinlike enhancer of split (TLE). [12] [13] [14] Elevated HES1 expression is correlated with several neoplastic conditions, and increased HES1 expression was found in multiple tumours, including non-small cell lung cancer, ovarian and colonic carcinomas and embryonal brain tumours. [15] [16] [17] [18] In addition, HES1 has been shown to promote cancer cell proliferation, cell survival and cell metastasis by evading tumour cell differentiation or regulating various signalling pathways. 5, 19, 20 Based on these results, we hypothesized that HES1 may participate in breast cancer progression. To date, the expression pattern and biological roles of HES1 in human breast cancer are unknown. In this study, we investigated the relationship between HES1 and breast cancers to determine whether HES1 is a contributor to malignancy and explored its underlying mechanism.
Materials and methods
This study was approved by the Institutional Review Board of the China Medical University, according to the Declaration of Helsinki. All participants provided written informed consent.
Patients and specimens
We collected 150 samples (32 cases of triple-negative breast cancer (TNBC) and 118 cases of non-TNBC) from patients diagnosed with primary breast cancer at The First Affiliated Hospital of the China Medical University between January 2009 and September 2011. The 150 patients enrolled in our study met the following criteria: (1) patients were diagnosed with invasive ductal breast cancer in clinical stages T1-T2, N0-N2 and M0; (2) none of the patients had received preoperational radiotherapy or chemotherapy; (3) all patients underwent complete surgical resection and (4) all patients received routine standardized treatment after surgery according to the National Comprehensive Cancer Network (NCCN) guidelines. Specimens from each individual were obtained through routine surgery dissections. All 150 patients were followed up for a median of 77.15 months (range: 12-84 months), and during follow-up, there were 26 patients who relapsed or progressed to metastasis and 25 deaths due to relapse or distant metastases.
Immunohistochemical analysis
Tumour samples were fixed with 10% neutral formalin, embedded in paraffin and sectioned into 4-µm-thick sections. Immunostaining was performed using the streptavidin-peroxidase immunohistochemical method. The sections were incubated overnight at 4°C with a rabbit monoclonal HES1-specific antibody (1:300 dilution; ab108937; Abcam, Cambridge, UK). As a blank control, phosphate-buffered saline was used in place of the antibody. The sections were then incubated with biotinlabelled secondary antibodies (Ultrasensitive; MaiXin, Fuzhou, China) at 37°C for 30 min and were then developed with diaminobenzidine.
Positive nuclear staining was defined as positive results. We calculated the percentage of positively stained cells. The staining intensity was categorized as follows: 0 = negative, 1 = weak, 2 = moderate and 3 = strong. The percentage of positively stained cells was scored as follows: 0 = no staining, 1 = ⩽10%, 2 = 11%-25%, 3 = 26%-50% and 4 = ⩾51%. The scores of each tumour sample were multiplied to yield a final score of 0-8; tumour samples with 4-8 were defined as HES1 positive/overexpression.
Cell culture and transfection
MCF-7 and MDA-MB-231 cell lines were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% foetal bovine serum (FBS) in a sterilized and humid incubator.
The HES1 (NM_005524) plasmid was purchased from GeneChem (GeneChem, Shanghai, China). Attractene Transfection Reagent (QIAGEN, Hilden, Germany) was used to transfect the HES1 plasmid according to the manufacturer's instructions. HES1 short hairpin RNA (shRNA) sequences (shHES1 1#: HES1-RNAi (4387-1) GCCA GTTTGCTTTCCTCAT; shHES1 2#: HES1-RNAi (4388-1) AGATCAATGCCATGACCTA and shHES1 3#: HES1-RNAi (4389-1) GGACATTCTGGAAATGACA) were synthesized by GeneChem and transfected into cells using DharmaFECT1 (QIAGEN) according to the manufacturer's directions. After 48 h of transfection, the protein levels were assessed using western blotting.
Western blot analysis
Total protein was extracted using the lysis buffer (Pierce, Rockford, IL, USA) and quantified through the Bradford method. Each 50 µg of protein sample was separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), and the membranes were incubated with antibodies against HES1 (1:500 dilution; ab108937; Abcam), phosphatase and tensin homologue (PTEN), p-AKT, AKT, E-cadherin, N-cadherin and vimentin (Cell Signaling Technology, Danvers, MA, USA) and anti-β-actin (Abcam) for overnight at 4°C. After incubation, the bound proteins were determined by enhanced chemiluminescence (ECL; Pierce) using a BioImaging System (UVP Inc., Upland, CA, USA).
3-(4,5-Dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide assay
The transfected cells were seeded on 96-well plates at a concentration of 3000 cells per well and incubated for 5 days. Then, 20 µL of 5 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; thiazolyl blue) dye solution was added to each well, and the plates were cultured for 4 h at 37°C. The MTT solution was removed, and 150 µL of dimethyl sulfoxide (DMSO) was used to solubilize the MTT formazan. The results were measured spectrophotometrically at a wavelength of 490 nm.
Transwell migration and Matrigel invasion assay
For the Transwell migration assay, 1 × 10 5 cells in 100 µL of DMEM without FBS were placed in the top chamber of Transwell migration chambers (8-µm BioCoat Control Inserts; Becton, Dickinson and Company; Becton Dickinson Labware, Bedford, MA, USA), and 600 µL of DMEM with 10% FBS was added to the lower chamber to serve as a chemoattractant. After incubation for 24 h, the non-migrated cells on the top surface of the Transwell membrane were removed with a cotton swab, and the migrated cells on the lower membrane surface were fixed and stained. The stained cells in five randomly selected high-power fields were then counted.
The procedure used for the Matrigel invasion assay was similar to that used for the Transwell migration assay, with the exception that the Transwell membrane was precoated with 20 mL of Matrigel (1:3 dilution; BD Biosciences, Bedford, MA, USA).
Statistical analysis
All statistical analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL, USA). The correlations between HES1 and clinicopathological factors were analysed by chi-square tests. Kaplan-Meier survival curves were prepared to evaluate the association between HES1 and patient survival, and the differences between subgroups of patients were compared through Cox regression analysis. p < 0.05 was considered to be statistically significant.
Results

Expression and localization of HES1 in breast cancer tissues
A panel of 150 primary breast cancer specimens and normal mammary gland tissues were analysed by immunohistochemistry. We found that HES1 protein was localized in the nuclear compartment. Negative staining was shown in the negative control using immunoglobulin. Negative expression of HES1 was found in normal breast samples (Figure 1(a) ). Weak nuclear expression was detected in five cases of ductal carcinoma in situ (DCIS; Figure 1(b) ). We found that HES1 was upregulated in 53 of 150 (35.3%) invasive ductal carcinoma (IDC) specimens. Weak/negative HES1 staining was considered normal (Figure 1(c) ). Strong/positive HES1 nuclear staining with a final score ⩾4 was considered as HES1 overexpression (Figure 1(d) ).
We analysed the relationship between HES1 expression and the clinical parameters to evaluate the biological role of HES1 in breast cancer progression. As shown in Table  1 , there were no correlations between HES1 overexpression and age (p = 0.082), tumour size (p = 0.097), progesterone receptor (PR) status (p = 0.107) and ErbB2 status (p = 0.407). However, significant correlations were observed between HES1 overexpression and advanced tumour-node-metastasis (TNM) stage (p = 0.011), positive node metastasis (p = 0.043) and negative oestrogen receptor (ER) status (p = 0.001). The rate of HES1 overexpression was higher in stage II-III breast cancers (36/81) than that in stage I (17/69) breast cancers. In addition, there were 24 cases with HES1 overexpression in all 32 cases of TNBC (ER-, PR-and human epidermal growth factor receptor 2 (HER2)-negative expression) and only 11 cases with HES1 overexpression in all 39 cases of triplepositive breast cancer (ER-, PR-and HER2-positive expression), which demonstrated that the proportion of HES1-positive samples was significantly higher in TNBCs than that in other breast cancer subtypes (p = 0.001), especially than that in triple-positive breast cancers (p < 0.001).
We also investigated HES1 expression using western blot analyses of freshly isolated breast cancer tissues. HES1 expression levels were significantly higher in the cancer samples compared with those of the corresponding normal samples (T vs N: 96.67 ± 18.01 vs 19.69 ± 3.94, respectively; p < 0.01; Figure 1 (e)).
We found that patients with low HES1 levels had increased survival relative to patients with high HES1 levels. The rates of 5-year progression-free survival (PFS) and overall survival (OS) of HES1-negative patients were significantly higher than those of HES1-positive patients as determined by Kaplan-Meier survival analysis (p < 0.05; Figure 2 (a) and (b)). Moreover, the 5-year PFS rates of patients with HES1-negative TNBC were statistically higher than those of patients with HES1-positive TNBC as determined using a Kaplan-Meier survival analysis (p = 0.041; Figure 2(c) ). Although there were no statistically significant differences in OS of patients with HES1positive and HES1-negative TNBC (p = 0.058; Figure  2(d) ), the 5-year OS rates of patients with HES1-positive TNBC were obviously lower than those in patients with HES1-negative TNBC. Thus, HES1 may be an important progressive and prognostic factor in breast cancers. 
HES1 promoted breast cancer cell proliferation and invasion by regulating the AKT signalling pathway and epithelial-mesenchymal transition process
To determine the biological effect of HES1 in breast cancer cells, we detected HES1 expression in a normal breast cell line (MCF-10A) and eight breast cancer cell lines using western blot analyses. We observed low levels of HES1 expression in the MCF-10A and MCF-7 cell lines and high levels of HES1 expression in the MDA-MB-231 and HCC-1937 cell lines (MCF-10A and MCF-7 vs MDA-MB-231 and HCC-1937: 145.0 ± 0.32 and 75.85 ± 0.04 vs 221.3 ± 0.50 and 237.6 ± 0.50, respectively; p < 0.001; Figure 3(a) ). MDA-MB-231 and HCC-1937 cell lines were both derived from TNBC specimens. We depleted HES1 in MDA-MB-231 cells using small interfering RNA (siRNA) and increased HES1 levels in MCF-7 cells via HES1 plasmid transfection. Western blot analyses confirmed the HES1 transfection and knockdown efficiencies. HES1 plasmid transfection in MCF-7 cells increased HES1 expression compared with cells transfected with a non-specific control (MCF-7 con vs HES1 plasmid (2 µg): 184 ± 5.7 vs 4.5 ± 0.1, respectively; p < 0.01; Figure 3(b) ). MDA-MB-231 cells treated with either HES1 shRNA2# or HES1 shRNA3# exhibited decreased HES1 expression in cells compared with cells treated with non-specific control (MDA-MB-231 con vs shRNA2#: 243.3 ± 0.4 vs 200.7 ± 4.1, respectively; MDA-MB-231 con vs shRNA3#: 243.3 ± 0.4 vs 186.7 ± 3.1, respectively; p < 0.01; Figure  3 (c)). MTT assays were performed to determine the effect of HES1 on breast cancer cell proliferation. We found that the HES1-specific siRNA treatment decreased cell survival compared with that of the control siRNA, and increased HES1 levels using HES1 plasmid transfection increased cell survival (Figure 4(a) and (b) ). These results indicate that HES1 is a crucial regulator of cell survival, cell size and proliferation in breast cancers. The role of HES1 in breast cancer cell migration and invasion was assessed using Transwell and Matrigel invasion assays. Our results showed that HES1 overexpression in MCF-7 cells promoted migration and invasion, and a significant decrease in cell migration and invasion was observed in cells with HES1 depletion compared with that of the scramble controls (Figure 4(c) and (d) ). These results indicated that HES1 regulates proliferation and invasion in breast cancer cells. Epithelial-mesenchymal transition (EMT) is a key mechanism that contributes to invasion and metastasis of various cancers. 21, 22 In addition, the matrix metalloproteinase (MMP) family members MMP2 and MMP9 facilitate cancer invasion by degrading the extracellular matrix (ECM). 23 To further analyse the potential mechanisms of HES1 in breast cancer cells, we investigated the expression levels of proteins involved in EMT and proteins belonging to the MMP family ( Figure 5(a) and (b) ). We found that there was no change in MMP2 and MMP9 expression levels following either upregulation of HES1 expression or silencing of HES1 expression. However, we observed a significant decrease in E-cadherin expression and a concurrent increase in N-cadherin and vimentin expression following HES1 overexpression. Conversely, depletion of HES1 using siRNA treatment resulted in increased E-cadherin expression and reduced N-cadherin and vimentin expression. These results indicated that HES1-induced migration and invasion in breast cancer cells are dependent on HES1-mediated EMT initiation. PTEN is a well-known tumour suppressor that negatively regulates the AKT pathway, which is a critical regulator of cell survival, proliferation and migration. 24, 25 Meanwhile, HES1 could also directly regulate PTEN expression by binding to the PTEN promoter. 26 Therefore, we investigated whether HES1-induced proliferation and invasion were mediated by inhibiting PTEN expression and activating the AKT pathway. Our results showed that upregulated HES1 expression in MCF-7 cells significantly decreased PTEN expression and substantially increased p-AKT levels, whereas HES1 knockdown increased PTEN expression and reduced AKT phosphorylation (i.e., the p-AKT/ AKT ratio) in MDA-MB-231 cells (Figure 5(c) and (d) ). These results suggested that HES1 regulates cell survival, proliferation and invasion via AKT signalling pathway activation. Based on these results, we propose that HES1 promotes breast cancer cell proliferation and invasion by regulating the AKT signalling pathway and EMT process.
Discussion
HES1 lies at the crossroads of multiple signalling pathways, and it is regarded as an excellent central target for treatment of multiple conditions. Although HES1 is usually considered a downstream targeted gene that is activated by the canonical Notch signalling pathway, HES1 expression is irrelevant to both activated and inactivated Notch signalling in Ewing's sarcoma family tumour (ESFT) cell lines. 27 Moreover, HES1 can also be enhanced via the hedgehog signalling pathway and other distinct pathways. 9, 10, 28 Therefore, HES1 levels are not always coupled with the activated Notch signalling pathway. The activation of these mentioned signalling pathways in breast cancer can regulate cell proliferation and migration, indicating that upregulated HES1 may play an important role in increasing invasion and metastasis of breast cancer. However, the expression pattern of HES1 itself and its definite biological roles in breast cancer have not been examined. In our study, we demonstrated that HES1 levels in invasive breast cancer were significantly higher than those in the normal breast tissues. Furthermore, upregulated HES1 expression correlated with advanced TNM stage and lymph node metastasis. The proportion of HES1 positive in TNBCs was significantly higher than that in other subtypes of breast cancers also including in triple-positive breast cancers. Similar outcomes were found in the breast cancer cell lines. TNBC is more aggressive and has decreased survival compared to that of other subtypes of breast cancers. These results not only revealed that high levels of HES1 were closely associated with TNBC and negative ER expression but also suggested that HES1 may be a critical contributor to TNBC. In addition, our study found that high HES1 expression was associated with unfavourable PFS and OS in breast cancer. Meanwhile, HES1 regulation was correlated with lower PFS and OS in patients with TNBC.
Moreover, a recent study revealed that HES1 upregulation predicts an unfavourable prognosis in TNBC. 29 To date, there is still no targeted and effective treatment strategy for TNBC due to deficiencies in therapeutic targets. Therefore, HES1 may be an independent prognostic factor for tumour progression and a potential therapeutic target in TNBC.
To analyse the potential mechanism by which upregulated HES1 promoted invasion of breast cancer cells, we tested the expression levels of invasion-related proteins and biological markers related to the EMT process. MMP2 and MMP9 are well-known cell migration-related proteins. 23 EMT is a process that is characterized by loss of epithelial cell polarization and cell adhesion and acquisition of mesenchymal characteristics and migration. These changes play a key role in morphogenesis during embryonic development and enhance epithelial-derived cancer invasion and metastasis and increase resistance to chemotherapy and radiotherapy. 21, 30 EMT is initiated with repression of E-cadherin, an epithelial marker, and acquisition of N-cadherin and vimentin, mesenchymal markers. 31 In our study, we blocked HES1 expression using siRNA treatment in the MDA-MB-231 cell line, which has high endogenous HES1 expression. We found that HES1 depletion resulted in a significant decrease in the proliferation rate and migratory capacity. HES1 upregulation in the MCF-7 cell line enhanced its invasion and proliferation, which was consistent with our immunohistochemical data. Downregulated HES1 increased E-cadherin expression and decreased N-cadherin and vimentin expression. These results indicated that HES1 promotes invasion and migration of breast cancer cell via EMT induction.
PTEN is well-known tumour repressor and a negative regulator of the AKT pathway, which endows cancer cells with proliferative, invasive and migratory properties. 24, 25 As a transcriptional repressor, HES1 could downregulate PTEN expression by binding to the PTEN promoter. 26 Our results showed that the knockdown of HES1 increased PTEN expression and decreased p-AKT protein levels and AKT activity, and overexpression of HES1 decreased PTEN expression and increased the p-AKT protein levels and AKT activity. These results revealed that HES1 suppressed PTEN expression and promoted activation of the AKT signalling pathway in breast cancer. They also indicated that HES1 may be an important contributor to the malignant biological behaviour of breast cancer cell via the AKT pathway and EMT modulation. EMT is crucial for breast cancer migration and invasion and is achieved through a well-orchestrated transcriptional programme. There are three families of transcription factors that act as repressors and bind to the E-cadherin promoter directly to induce EMT -these proteins include Snail, Slug, ZEB1, ZEB2, SIP1, E47 and Twist. 32, 33 AKT plays a critical role in cell survival, proliferation and migration. AKT is a key mediator of EMT in human epithelial malignancies. 34 However, the mechanisms by which HES1 triggers EMT in breast cancer are currently unclear. Whether activating the AKT pathway mediates HES1-induced EMT indirectly or whether HES1 promotes EMT directly via suppression of E-cadherin by binding to its transcriptional promoter or activation of E-cadherin transcriptional repressors, such as Snail, Slug, ZEB1, ZEB2, SIP1, E47 and Twist, should be elucidated in our future studies. HES1 was reported to enhance signal transducer and activator of transcription-3 (STAT3) phosphorylation by binding to STAT3 directly, and phosphorylated STAT3 can elevate MMP2 and MMP9 expression by directly binding to their promoters. [35] [36] [37] In our study, we observed that overexpression or depletion of HES1 had no effect on MMP2 and MMP9 expression.
In conclusion, this study showed that increased HES1 was found in breast cancer tissues, and high levels of HES1 were positively correlated with advanced TNM stage and TNBC. HES1 played a crucial role in malignant cell proliferation and invasion via regulation of the AKT pathway and EMT process in breast cancer. These results suggested that HES1 may be an important regulator of breast cancer progression and a potential therapeutic target in TNBC treatment. Further studies should investigate the possibility of targeting HES1 in TNBC.
